Stanford University
Showing 10,881-10,890 of 14,431 Results
-
Morteza Roodgar DVM, PhD
Veterinarian Research Scientist, Genetics
BioDr. Morteza Roodgar is a veterinarian scientist with a research focus on Primate induced Pluripotent Stem Cells (iPSCs) and long-read genomics tools.
Dr. Roodgar's research focus is on primate stem cell biology, immunology, and comparative genomics of nonhuman primate models for human diseases. The long-term goal of Dr. Roodgar's research is to Replace, Reduce and Refine (aka 3 R’s) the use of animals in biomedical research leveraging primate induced pluripotent stem cells (iPSCs) and long-read genomic tools to speed up preclinical testing.
Previous research includes immunology and genomic susceptibility to infectious diseases (e.g., tuberculosis, TB) in nonhuman primate models, Preventive Veterinary Medicine and emerging zoonotic diseases (e.g., COVID-19 and Monkeypox). -
Michal Bental Roof
Academic Prog Prof 3, Pediatrics - Cardiology
Current Role at StanfordI joined the Cardiopulmonary Research Program of Drs. Rabinovitch and Bland at Stanford University in 2002, as the Academic and Research Program Officer, and since 2020 assumed my role at the Basic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, directed by Dr. Rabinovitch. I organize the educational activities of the lab, and assist the faculty and fellows with the preparation of grant proposals, IRB, APLAC and Biosafety protocols, manuscripts, and presentations. I served as the Site Coordinator for the Stanford Transplant Procurement Center of the Pulmonary Hypertension Breakthrough Initiative (PHBI), headed by Dr. Rabinovitch,that now evolved into the Stanford Transplant Tissue Bank. In this capacity, I oversee patient recruitment, data collection and reporting, and ensure compliance with university and federal guidelines. I coordinated and prepared the application for an Investigational New Drug (IND) and the pre-IND meeting that preceded that, for Elafin as a therapy for pulmonary arterial hypertension (PAH) to the FDA in August 2017, and with the Study PIs coordinated the Phase 1 clinical trial “Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects” that followed.
From 2005-2015, I served as the Administrative Coordinator of the Cardiovascular and Pulmonary Science Scholarly Concentration for medical students at Stanford University School of Medicine. This includes facilitating communication of the four co-Directors with the School of Medicine Administration, the medical students, and the faculty mentors. An important component of this role is the coordination of the MED223 course, a medical school course where faculty and fellows present new developments in cardiovascular science in the form of a journal club. From 2013-2018, I was the coordinator for the NIH-NHLBI T32 “Mechanisms and Innovation in Vascular Disease” (PI: RL Dalman), and from 2013 to date for NIH-NHLBI K12 HL120001 “Stanford Career Development Program in ‘Omics’ of Lung Disease”. (PIs: M Rabinovitch, MR Nicolls and MP Snyder). This included recruitment of candidates, oversight of training activities, ensuring compliance with NIH and Stanford policies, and acting as a liaison between the trainees and the Directors to facilitate effective communication.
Prior to joining Stanford, I was Associate Director (Scientific Development Administrator) at the Institute for Medicine and Engineering, directed by Dr. Peter Davies at the University of Pennsylvania. In this role, I was the liaison with federal funding agencies and organized multi-investigator program projects and training grants.
